Affimed N.V. (AFMD) Analysis & Forecast for January 2021

Affimed N.V. (NASDAQ: AFMD) is 13.75% higher on its value in year-to-date trading and has touched a low of $1.42 and a high of $7.46 in the current 52-week trading range. The AFMD stock was last observed hovering at around $6.62 in the last trading session, with the day’s gains setting it 0.27% off its average median price target of $8.13 for the next 12 months. It is also 23.27% off the consensus price target high of $8.98 offered by 5 analysts, but current levels are -4.71% lower than the price target low of $6.58 for the same period.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Currently trading at $6.89, the stock is 8.48% and 26.62% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.97 million and changing 4.15% at the moment leaves the stock 80.12% off its SMA200. AFMD registered 147.01% gain for a year compared to 6-month gain of 59.13%. The firm has a 50-day simple moving average (SMA 50) of $6.14 and a 200-day simple moving average (SMA200) of $4.35.

The stock witnessed a -1.34% loss in the last 1 month and extending the period to 3 months gives it a 80.38%, and is 11.64% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.76% over the week and 6.98% over the month.

Affimed N.V. (AFMD) has around 128 employees, a market worth around $609.30M and $27.70M in sales. Distance from 52-week low is 385.56% and -7.57% from its 52-week high. The company has generated returns on investments over the last 12 months (-77.40%).

Affimed N.V. (AFMD) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Affimed N.V. (AFMD) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.60, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Affimed N.V. is expected to release its quarterly report on 05/19/2021 and quarterly earnings per share for the current quarter are estimated at $0 with sales reaching $17.34M over the same period.The EPS is expected to shrink by -56.50% this year, but quarterly earnings will post 84.70% year-over-year. Quarterly sales are estimated to grow 341.90% in year-over-year returns.

Affimed N.V. (AFMD) Top Institutional Holders

137 institutions hold shares in Affimed N.V. (AFMD), with 5.66M shares held by insiders accounting for 6.41% while institutional investors hold 59.06% of the company’s shares. The shares outstanding are 86.03M, and float is at 82.67M with Short Float at 7.12%. Institutions hold 55.27% of the Float.

The top institutional shareholder in the company is NEA Management Company, LLC with over 6.13 million shares valued at $20.77 million. The investor’s holdings represent 9.82% of the AFMD Shares outstanding. As of Sep 29, 2020, the second largest holder is Blackrock Inc. with 5.05 million shares valued at $17.12 million to account for 8.09% of the shares outstanding. The other top investors are Millennium Management LLC which holds 4.25 million shares representing 6.81% and valued at over $14.4 million, while 683 Capital Management LLC holds 5.85% of the shares totaling 3.65 million with a market value of $12.37 million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Affimed N.V. (AFMD): Who are the competitors?

The company’s main competitors (and peers) include Acorda Therapeutics Inc. (ACOR) that is trading -70.80% down over the past 12 months. Short interest in the company’s stock has risen 7.95% from the last report on Nov 29, 2020 to stand at a total of 5.67 million short shares sold with a short interest ratio of 3.66.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free